Liu SY et al.17 showed that the anti-tumor activity of Tislelizumab is stronger than traditional PD-1 monoclonal antibodies and is beneficial for improving tumor control rate and prolonging patient survival cycle. This evidence concerns the gene PDCD1 and neoplasm.